Jobtacular.com
Claim This Podcastby Telehealth FX
Podcast Authority
Beta
Podcast Overview
<p>Welcome to TelehealthFX Talk, the evidence-based podcast that cuts through the hype of the rapidly evolving world of clinical weight loss and metabolic medicine.Whether you are navigating the transition to GLP-1 medications like semaglutide and tirzepatide, exploring complementary therapies like sermorelin and NAD+, or looking for natural metabolic support with berberine, we provide the honest, research-backed science you need to make informed decisions. </p><p><br></p><p>Each week, we break down complex topics—from managing side effects and breaking through weight loss plateaus to preserving lean muscle mass and understanding the latest FDA updates.It is time to silence the food noise and optimize your metabolic health. Hit subscribe to stay up-to-date with the latest breakthroughs in clinical wellness, and visit us at telehealthfx.com to learn more about our comprehensive clinical programs.</p>
Language
🇺🇲
Publishing Since
6/18/2025
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
Podcast Authority
BetaRecommendations available
Unlock the full report to see detailed tips
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
See how your show performs across every key metric
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
2 verified contact emails on file for Jobtacular.com
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
May 31, 2026
Tirzepatide, Explained: Mounjaro vs. Zepbound, How It Works & Why It's a Sleep Apnea Drug Now
<p>Learn more or see if you may qualify at <a href="https://telehealthfx.com/" target="_blank">https://telehealthfx.com</a></p><p>Educational content only — not medical advice. Talk to a licensed clinician before starting any medication. Telehealth FX is an informational and affiliate platform, not a medical provider or pharmacy, and may earn a commission. Compounded medications are not FDA-approved. Individual results vary.</p><p>Tirzepatide is the medication behind Mounjaro and Zepbound — and unlike single-receptor GLP-1s, it's a dual GIP/GLP-1 agonist. In this episode we explain what tirzepatide is, how the two-receptor mechanism works, the difference between the brands, what the research shows for weight and blood sugar, how it compares to semaglutide, and why it recently became the first medication ever approved for obstructive sleep apnea — plus the real side effects and the honest truth about stopping.</p><p>Quick clarifier: tirzepatide is the active drug. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management and, as of December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity.</p><p>Key facts: In SURMOUNT-1, average weight loss ranged from about 16% to 22.5% over 72 weeks. In the head-to-head SURMOUNT-5 trial, tirzepatide produced about 20.2% weight loss versus 13.7% for semaglutide. In SURMOUNT-OSA, the highest tolerated doses were associated with roughly 25–29 fewer apnea/hypopnea events per hour versus placebo. Across follow-up studies, people regained roughly two-thirds of lost weight within a year of stopping.</p><p>Real risks discussed: gastrointestinal side effects; a boxed warning for thyroid C-cell tumors (not for those with a personal/family history of medullary thyroid carcinoma or MEN2); pancreatitis and gallbladder risks; a class warning for ileus (intestinal blockage). Note: a large analysis did not find a significant link between tirzepatide and the rare optic-nerve condition associated with semaglutide, though research continues.</p><p>Important: Compounded tirzepatide is not FDA-approved — the FDA does not evaluate it for safety, effectiveness, or quality — and it is not the same as branded Mounjaro or Zepbound. Prescription medications require evaluation and a prescription from a licensed clinician, and eligibility is individual. Individual results vary.</p><p>Learn more or see if you may qualify at <a href="https://telehealthfx.com" target="_blank">https://telehealthfx.com</a></p><p>#Tirzepatide #Mounjaro #Zepbound #WeightManagement #SleepApnea #GLP1 #HealthEducation #Telehealth</p>
May 31, 2026
Semaglutide, Explained: Ozempic vs. Wegovy vs. the New Pill, Side Effects & How It Works
<p>Viit <a href="https://telehealthfx.com/" target="_blank">https://telehealthfx.com</a> to get started. </p><p>Educational content only — not medical advice. Talk to a licensed clinician before starting any medication. Telehealth FX is an informational and affiliate platform, not a medical provider or pharmacy, and may earn a commission. Compounded medications are not FDA-approved. Individual results vary.</p><p>Semaglutide goes by a lot of names — Ozempic, Wegovy, Rybelsus, and now the new Wegovy pill — and the confusion is real. In this episode we explain what semaglutide actually is, how it works, the difference between the brands, how well it works for weight management, what the research says about heart health, how it compares to tirzepatide, the real side effects, and the honest truth about what happens when you stop.</p><p>Quick clarifier: semaglutide is the active drug. Ozempic is the injection approved for type 2 diabetes; Wegovy is the injection approved for weight management; Rybelsus is the oral tablet for type 2 diabetes. In December 2025 the FDA approved a once-daily oral semaglutide (Wegovy pill) for chronic weight management.</p><p>Key facts: In the STEP 1 trial, average weight loss with semaglutide 2.4 mg injection was about 14.9% over 68 weeks. In the OASIS 4 trial, the oral 25 mg pill produced about 13.6% average weight loss (around 16.6% with full adherence), described as similar to the injection. In the SELECT trial, semaglutide was linked to about a 20% reduction in major cardiovascular events in people with overweight/obesity and established heart disease. In the head-to-head SURMOUNT-5 trial, semaglutide produced about 13.7% weight loss versus 20.2% for tirzepatide. Across follow-up studies, people regained roughly two-thirds of lost weight within a year of stopping.</p><p>Real risks discussed: gastrointestinal side effects; a boxed warning for thyroid C-cell tumors (not for those with a personal/family history of medullary thyroid carcinoma or MEN2); pancreatitis and gallbladder risks; and an eye-condition signal still under study.</p><p>Important: Compounded semaglutide is not FDA-approved — the FDA does not evaluate it for safety, effectiveness, or quality — and it is not the same as branded Ozempic or Wegovy. Prescription medications require evaluation and a prescription from a licensed clinician, and eligibility is individual. Individual results vary.</p><p>Learn more or see if you may qualify at <a href="https://telehealthfx.com" target="_blank">https://telehealthfx.com</a></p><p>#Semaglutide #Ozempic #Wegovy #Rybelsus #WeightManagement #GLP1 #HealthEducation #Telehealth</p>
May 31, 2026
How Well Do GLP-1s Actually Work? Semaglutide, Tirzepatide & the New Pill, Explained
<p>Visit https://losingweightrx.com to get started.</p><p>Educational content only — not medical advice. Talk to a licensed clinician before starting any medication. Telehealth FX is an informational and affiliate platform, not a medical provider or pharmacy, and may earn a commission. Compounded medications are not FDA-approved. Individual results vary.</p><p>In this episode we look at what the science actually says about how well GLP-1 medications work for weight management — and what "effective" really means once you look past the first few months. We cover how semaglutide and tirzepatide work, the headline results from the major clinical trials, the newly approved any-time-of-day GLP-1 pill, the cardiovascular findings that go beyond the scale, and the honest catch most ads skip: these medications work while you take them, and much of the lost weight tends to return after stopping.</p><p>Key facts: In the STEP 1 trial, average weight loss with semaglutide 2.4 mg was about 14.9% over 68 weeks. In SURMOUNT-1, tirzepatide produced roughly 16–22% average loss depending on dose. In the SELECT trial, semaglutide was linked to about a 20% reduction in major cardiovascular events in people with overweight/obesity and established heart disease. The newly approved oral GLP-1 showed up to about 12.4% weight loss at its highest dose over 72 weeks. Across follow-up studies, people regained roughly two-thirds of lost weight within a year of stopping.</p><p>Real risks discussed: gastrointestinal side effects; a boxed warning for thyroid C-cell tumors (not for those with a personal/family history of medullary thyroid carcinoma or MEN2); pancreatitis and gallbladder risks; and an eye-condition signal still under study.</p><p>Important: Compounded semaglutide and tirzepatide are not FDA-approved — the FDA does not evaluate them for safety, effectiveness, or quality — and they are not the same as branded Ozempic, Wegovy, Mounjaro, or Zepbound. Prescription medications require evaluation and a prescription from a licensed clinician, and eligibility is individual. Individual results vary.</p><p>Learn more or see if you may qualify at <a href="https://telehealthfx.com" target="_blank">https://telehealthfx.com</a></p><p>#GLP1 #Semaglutide #Tirzepatide #WeightManagement #ObesityMedicine #HealthEducation #Telehealth</p>
48 total episodes available
Similar Podcasts
Discover related shows you might enjoy
Deep-dive analytics for Jobtacular.com
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Jobtacular.com?
<p>Welcome to TelehealthFX Talk, the evidence-based podcast that cuts through the hype of the rapidly evolving world of clinical weight loss and metabolic medicine.Whether you are navigating the transition to GLP-1 medications like semaglutide and tirzepatide, exploring complementary therapies like sermorelin and NAD+, or looking for natural metabolic support with berberine, we provide the honest, research-backed science you need to make informed decisions. </p><p><br></p><p>Each week, we break down complex topics—from managing side effects and breaking through weight loss plateaus to preserving lean muscle mass and understanding the latest FDA updates.It is time to silence the food noise and optimize your metabolic health. Hit subscribe to stay up-to-date with the latest breakthroughs in clinical wellness, and visit us at telehealthfx.com to learn more about our comprehensive clinical programs.</p> - How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.